Interest of the Peak of Reticulocytes in Chronic Hemodialysis Patients Treated by Mircera

Trial Profile

Interest of the Peak of Reticulocytes in Chronic Hemodialysis Patients Treated by Mircera

Recruiting
Phase of Trial: Phase III

Latest Information Update: 23 Oct 2017

At a glance

  • Drugs Methoxy polyethylene glycol-epoetin beta (Primary)
  • Indications Anaemia
  • Focus Therapeutic Use
  • Acronyms RETICERA
  • Most Recent Events

    • 22 Jun 2017 Planned End Date changed from 1 Jul 2018 to 22 Dec 2019.
    • 22 Jun 2017 Planned primary completion date changed from 1 Jan 2018 to 22 Dec 2018.
    • 19 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top